Max Planck Innovation

What Max Planck Innovation does

Max-Planck-Innovation GmbH is the wholly-owned technology transfer organization of the Max-Planck-Gesellschaft (Max Planck Society), Germany's largest publicly funded basic research body. Headquartered in Munich since 1970, the company serves as the exclusive commercial interface for IP emanating from 80+ Max Planck Institutes, which collectively publish more than 15,000 scientific contributions per year. Its mandate is to convert basic research into economic and societal utility through three core service lines: Patent & License Management (invention evaluation, patent filing, and license negotiation), Start-up Management (from initial spin-off ideation through business plan, fundraising, and company founding), and a diversified Technology Offerings portfolio spanning 13 categories including analytics, IT/software, life sciences, microscopy, photonics, quantum technologies, and fusion energy.

Operationally, Max Planck Innovation runs two flagship programs that sit on top of the core services: the MAX!mize incubator, which delivers individualized curriculum, mentorship, and networking to MPG researchers, and the Prove2Move validation program, launched in 2026 with an annual €4M budget to de-risk early-stage technologies that are otherwise too immature for licensees or investors. The business model is multi-stream: revenue is generated through licensing royalties (one-time fees, milestone payments, revenue shares, and annual minimum royalties on the ~2,800 exploitation contracts concluded to date and ~80 new agreements signed annually), equity stakes retained in spin-offs (e.g., QLi5, Batene, Meshcapade, Ovo Labs), and to a lesser extent event-driven investor matching (4Investors Day, BioVaria). Customers split into three segments — industrial licensees (pharma, biotech, microscopy, battery tech, and adjacent verticals), MPG researchers seeking commercialization support, and VC/family-office investors seeking deep-tech deal flow. Geographic reach spans Germany, broader Europe, the United States, and Japan.

Recent strategic activity underscores both the scale and the momentum of the model: MPG spin-offs launched 14 new startups in 2025 (nearly double the prior year), produced four unicorns with a combined capital valuation exceeding €67B, and achieved marquee exits such as Epic Games' acquisition of Meshcapade (with Max Planck Innovation retaining SMPL licensing rights). Strategic partners include Bayer, Leica Microsystems, Alnylam Pharmaceuticals, Gelion PLC, the Lead Discovery Center, SPRIND, and the Schwarz Gruppe. The organization is privately held and does not disclose revenue; its growth is measured primarily through portfolio throughput, spin-off formation, license deal volume, and the equity value created in portfolio companies rather than top-line figures.

Name

Max Planck Innovation

Legal name

Max-Planck-Innovation GmbH

Website

https://max-planck-innovation.de

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

11–50 employees

Short description

Max-Planck-Innovation GmbH is the wholly-owned technology transfer organization of the Max Planck Society, managing its patent portfolio, executing ~80 new license agreements annually, and supporting deep-tech spin-offs across life sciences, materials, microscopy, photonics, quantum, and fusion for global industrial partners and investors.

Ownership category

akta.pro rank

Product category

Technology Transfer Services

NAICS

Scientific Research and Development Services (5417), Professional, Scientific, and Technical Services (541)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Engineering Services (8711)

akta.pro primary industry

Standards-Essential Patents (SEP) & FRAND Advisory (BPAHAMAL)

Keywords

• Technology transfer services
• Patent licensing
• Spin-off incubation
• IP commercialization
• Research-to-market

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Patent and Technology Licensing: Max Planck Innovation generates revenue through licensing agreements with industrial partners for patented technologies and know-how. Approximately 80 new license agreements are signed each year, and roughly 2,800 exploitation contracts have been concluded to date. License structures include one-time payments, revenue shares, milestone payments (e.g., in drug development), and annual minimum royalties.
2. Equity Stakes in Spin-offs: Max Planck Innovation holds equity stakes in spin-off companies founded from Max Planck research (e.g., QLi5, Batene, Meshcapade, Ovo Labs). Returns on these equity positions contribute to revenue and reflect successful commercialization of MPG IP.

Go-to-market motion4 records

Distribution channels3 records

Marketing channels7 records

Core offering

Max-Planck-Innovation GmbH is the central technology transfer organization for the Max Planck Society (MPG). It evaluates inventions from 80+ Max Planck Institutes, files and prosecutes patents, negotiates license agreements with industrial partners across pharma, biotech, microscopy, materials, photonics, quantum tech, and fusion energy, and supports Max Planck researchers in founding spin-off companies. It operates the MAX!mize startup incubator and the Prove2Move €4M/year validation program, currently managing roughly 2,800 cumulative exploitation contracts with about 80 new license agreements signed each year.

Product overview

Max Planck Innovation is the technology transfer organization for the Max Planck Society, responsible for managing patents, licenses, and spin-offs from Max Planck research institutes. The organization operates as a service provider rather than a product company, offering three core services: Patent & License Management (advisory on evaluating and patenting research results, plus license negotiation), Start-up Management (comprehensive consulting for spin-offs from business plan through fundraising), and a portfolio of Technology Offerings (patents and know-how available for licensing across diverse categories). Key programs include the MAX!mize Start-up Incubator Program providing tailored incubation for researchers, and the Prove2Move Validation Program with annual funding of four million euros. The technology offerings portfolio spans multiple domains including life sciences, materials science, photonics, quantum technologies, and fusion technology, with specific technologies highlighted such as an ultrarapid cryo-fixation microscopy module, nanographene-based dyes for super-resolution microscopy, nanoporous polymer films, an ultracompact medical ventilation system, RNA-based therapeutics platforms, and various diagnostic and analytical technologies.

Differentiator

Problem solved

Functional benefit

Brands

• MAX!mize: Startup incubation program for Max Planck researchers providing individual support, customized curriculum, and networking opportunities to transfer founding ideas into successful startups.

Products and services

• Patent & License Management Advisory services for Max Planck researchers on evaluating and patenting research results, plus license contract negotiation support for both researchers and industrial partners. Includes invention disclosure assessment, patent filing decisions, and structuring of license agreements (upfront fees, milestones, royalties, annual minimums).
• Start-up Management Comprehensive consulting for Max Planck scientists from evaluating spin-off ventures through to fundraising support, including business plan development and startup incubation assistance. Covers initial consultations, business plan development, funding program guidance, fundraising support, and team-completion advice.
• Technology Offerings Portfolio (Lizenzierbare Technologieangebote) Portfolio of patents and know-how from Max Planck Institutes available for licensing, spanning 13 categories including Analytik, IT/Software/Bioinformatik, Medizin, Prozesse und Methoden, Forschungs-Reagenzien, Nukleinsäure/Protein/Zell-bezogene Technologien, Grüne Biotechnologie, Bildgebung und Mikroskopie, Neue Materialien, Sensoren/Geräte/Komponenten, Photonics, Quantentechnologien, and Fusionstechnologie/-energie. Represents ~80 new license agreements per year.
• MAX!mize Start-up Incubator Program Incubation program providing aspiring Max Planck researchers with individualized support, a tailored curriculum, and networking opportunities to transfer founding ideas into successful start-ups. Operates as a sub-brand of Max-Planck-Innovation.
• Prove2Move Validation Program Annual four-million-euro funding program designed to help Max Planck researchers validate early-stage technologies and reduce technological risks before commercialization. Addresses the gap where licensees and investors consider early-stage validation too risky; supports subsequent licensing or spin-off formation.

Quantifiable outcome

• Four unicorn spin-offs with combined capital valuation exceeding €67B, and a #2 ranking among European research organizations for deep tech and life science spin-offs
• +3 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• Gelion PLCcoreTechnology or Integration · 1 June 2026Gelion PLC signed an exclusive commercial licence agreement with Max-Planck-Innovation GmbH securing long-term global rights to intellectual property covering nano-encapsulated sulfur cathode technology and novel nano-confined anode materials for sulfur batteries. The deal formalizes an option secured in March 2025 and includes staged cash payments and royalties over net sales.
• Lead Discovery Center (LDC)coreStrategic or Co-development Partner · 1 December 2025The Lead Discovery Center (LDC) is a joint venture between the Max Planck Society and the Lead Discovery Center GmbH, co-founding spin-offs such as QLi5 Therapeutics together with Qurient and Nobel laureate Prof. Robert Huber. The LDC bridges the gap between academic research and the pharmaceutical industry in early drug discovery, and co-develops therapeutic approaches with MPG researchers.
• BioVaria (Main Partner)flagshipStrategic or Co-development PartnerMax Planck Innovation is a main partner (alongside the Lead Discovery Center) of the BioVaria conference, an annual platform connecting life science innovations from research institutions with industry and investors. At BioVaria 2026, Max Planck Innovation presented four breakthrough technologies from MPG institutes in areas including RNA therapeutics, single-cell sequencing, and lung function diagnostics.
• BayercoreTechnology or IntegrationBayer has licensed MPG technology that led to the development of a new cancer treatment approach currently in Phase 1 clinical trial, through a cooperation between the Lead Discovery Center and Bayer HealthCare. Bayer's Senior Vice President for Global Drug Discovery cited Max Planck Innovation as providing excellent access to the technology portfolio of various Max Planck Institutes.
• Leica MicrosystemscoreTechnology or IntegrationLeica Microsystems licensed Nobel laureate Stefan Hell's STED and GSDIM super-resolution microscopy technologies from the Max Planck Institute for Biophysical Chemistry, resulting in products that set new standards in the life sciences and enabled discoveries in virology, neuroscience, and oncology.
• Alnylam PharmaceuticalscoreTechnology or IntegrationAlnylam Pharmaceuticals has maintained a long-standing IP partnership with Max Planck Innovation since 2002 for the development of RNAi therapeutics. Alnylam's CEO cited Max Planck Innovation as a strong partner in the development of RNAi therapeutics for the benefit of patients.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/MP_Innovation
• YouTubeyoutube.com/@Max-Planck-Innovation
• LinkedInlinkedin.com/company/max-planck-innovation-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Max Planck Innovation